These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37834363)

  • 1. Inflammatory Blood Biomarkers Are Associated with Long-Term Clinical Disease Severity in Parkinson's Disease.
    Hepp DH; van Wageningen TA; Kuiper KL; van Dijk KD; Oosterveld LP; Berendse HW; van de Berg WDJ
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
    Liu T; Zuo H; Ma D; Song D; Zhao Y; Cheng O
    J Neuroinflammation; 2023 Jul; 20(1):167. PubMed ID: 37475029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.
    Schrag A; Siddiqui UF; Anastasiou Z; Weintraub D; Schott JM
    Lancet Neurol; 2017 Jan; 16(1):66-75. PubMed ID: 27866858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression.
    Santos-García D; Mir P; Cubo E; Vela L; Rodríguez-Oroz MC; Martí MJ; Arbelo JM; Infante J; Kulisevsky J; Martínez-Martín P;
    BMC Neurol; 2016 Feb; 16():26. PubMed ID: 26911448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Parkinson's disease using blood-based biomarkers: A multicohort proteomic analysis.
    Posavi M; Diaz-Ortiz M; Liu B; Swanson CR; Skrinak RT; Hernandez-Con P; Amado DA; Fullard M; Rick J; Siderowf A; Weintraub D; McCluskey L; Trojanowski JQ; Dewey RB; Huang X; Chen-Plotkin AS
    PLoS Med; 2019 Oct; 16(10):e1002931. PubMed ID: 31603904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease.
    Bartl M; Dakna M; Schade S; Otte B; Wicke T; Lang E; Starke M; Ebentheuer J; Weber S; Toischer K; Schnelle M; Sixel-Döring F; Trenkwalder C; Mollenhauer B
    Mov Disord; 2023 Jan; 38(1):68-81. PubMed ID: 36267007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD).
    Williams-Gray CH; Wijeyekoon R; Yarnall AJ; Lawson RA; Breen DP; Evans JR; Cummins GA; Duncan GW; Khoo TK; Burn DJ; Barker RA;
    Mov Disord; 2016 Jul; 31(7):995-1003. PubMed ID: 26999434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.
    Kang JH; Irwin DJ; Chen-Plotkin AS; Siderowf A; Caspell C; Coffey CS; Waligórska T; Taylor P; Pan S; Frasier M; Marek K; Kieburtz K; Jennings D; Simuni T; Tanner CM; Singleton A; Toga AW; Chowdhury S; Mollenhauer B; Trojanowski JQ; Shaw LM;
    JAMA Neurol; 2013 Oct; 70(10):1277-87. PubMed ID: 23979011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa).
    Mollenhauer B; Zimmermann J; Sixel-Döring F; Focke NK; Wicke T; Ebentheuer J; Schaumburg M; Lang E; Friede T; Trenkwalder C;
    Mov Disord; 2019 Jan; 34(1):67-77. PubMed ID: 30468694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytokine profiles of plasma extracellular vesicles as progression biomarkers in Parkinson's disease.
    Chan L; Chung CC; Yu RC; Hong CT
    Aging (Albany NY); 2023 Mar; 15(5):1603-1614. PubMed ID: 36897204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.
    Nalls MA; McLean CY; Rick J; Eberly S; Hutten SJ; Gwinn K; Sutherland M; Martinez M; Heutink P; Williams NM; Hardy J; Gasser T; Brice A; Price TR; Nicolas A; Keller MF; Molony C; Gibbs JR; Chen-Plotkin A; Suh E; Letson C; Fiandaca MS; Mapstone M; Federoff HJ; Noyce AJ; Morris H; Van Deerlin VM; Weintraub D; Zabetian C; Hernandez DG; Lesage S; Mullins M; Conley ED; Northover CA; Frasier M; Marek K; Day-Williams AG; Stone DJ; Ioannidis JP; Singleton AB;
    Lancet Neurol; 2015 Oct; 14(10):1002-9. PubMed ID: 26271532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Senescence and Inflammatory Markers for Predicting Clinical Progression in Parkinson's Disease: The ICICLE-PD Study.
    Martin-Ruiz C; Williams-Gray CH; Yarnall AJ; Boucher JJ; Lawson RA; Wijeyekoon RS; Barker RA; Kolenda C; Parker C; Burn DJ; Von Zglinicki T; Saretzki G
    J Parkinsons Dis; 2020; 10(1):193-206. PubMed ID: 31868677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson's disease patients.
    Swanson CR; Berlyand Y; Xie SX; Alcalay RN; Chahine LM; Chen-Plotkin AS
    Mov Disord; 2015 Oct; 30(12):1648-56. PubMed ID: 26207725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with
    Sheng ZH; Ma LZ; Liu JY; Ou YN; Zhao B; Ma YH; Tan L
    Front Aging Neurosci; 2022; 14():1061096. PubMed ID: 36589544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson's Disease: Data from the PPMI Study.
    Koros C; Simitsi AM; Papadimitriou D; Bougea A; Prentakis A; Papagiannakis N; Pachi I; Bozi M; Antonelou R; Angelopoulou E; Beratis I; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    J Parkinsons Dis; 2020; 10(2):481-487. PubMed ID: 32176655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral innate immune and bacterial signals relate to clinical heterogeneity in Parkinson's disease.
    Wijeyekoon RS; Kronenberg-Versteeg D; Scott KM; Hayat S; Kuan WL; Evans JR; Breen DP; Cummins G; Jones JL; Clatworthy MR; Floto RA; Barker RA; Williams-Gray CH
    Brain Behav Immun; 2020 Jul; 87():473-488. PubMed ID: 32006615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA sequencing of whole blood reveals early alterations in immune cells and gene expression in Parkinson's disease.
    Craig DW; Hutchins E; Violich I; Alsop E; Gibbs JR; Levy S; Robison M; Prasad N; Foroud T; Crawford KL; Toga AW; Whitsett TG; Kim S; Casey B; Reimer A; Hutten SJ; Frasier M; Kern F; Fehlman T; Keller A; Cookson MR; Van Keuren-Jensen K;
    Nat Aging; 2021 Aug; 1(8):734-747. PubMed ID: 37117765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.
    Simuni T; Caspell-Garcia C; Coffey CS; Weintraub D; Mollenhauer B; Lasch S; Tanner CM; Jennings D; Kieburtz K; Chahine LM; Marek K
    J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):78-88. PubMed ID: 28986467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.